Junko Nagai
Overview
Explore the profile of Junko Nagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagai J, Ishikawa Y
PLoS One
. 2021 Dec;
16(12):e0260980.
PMID: 34855908
Introduction: Anticholinergic adverse effects (AEs) are a problem for elderly people. This study aimed to answer the following questions. First, is an analysis of anticholinergic AEs using spontaneous adverse drug...
2.
Takao K, Takemura Y, Nagai J, Kamauchi H, Hoshi K, Mabashi R, et al.
Bioorg Med Chem
. 2021 Jun;
42:116255.
PMID: 34119696
A series of 3-styrylchromone derivatives was synthesized and evaluated for monoamine oxidase (MAO) A and B inhibitory activities. Most of all derivatives inhibited MAO-B selectively, except compound 21. Compound 19,...
3.
Kan Y, Nagai J, Uesawa Y
Sci Rep
. 2021 May;
11(1):9625.
PMID: 33953272
Adverse effects can occur owing to anorexia, which can reduce treatment compliance and worsen the patients overall condition. One such side effect, namely drug-induced taste and smell disorders, reduces patients...
4.
Teratani M, Nakamura S, Sakagami H, Fujise M, Hashimoto M, Okudaira N, et al.
Anticancer Res
. 2020 Sep;
40(9):4885-4894.
PMID: 32878776
Aim: The aim of this study was to investigate the antitumor potential of guaiazulene-3-carboxylate derivatives against oral malignant cells. Materials And Methods: Twelve guaiazulene-3-carboxylate derivatives were synthesized by introduction of...
5.
Sugita Y, Takao K, Uesawa Y, Nagai J, Iijima Y, Sano M, et al.
Medicines (Basel)
. 2020 Aug;
7(9).
PMID: 32858984
Since many anticancer drugs show severe adverse effects such as mucositis, peripheral neurotoxicity, and extravasation, it was crucial to explore new compounds with much reduced adverse effects. Comprehensive investigation with...
6.
Usami Y, Higuchi M, Mizuki K, Yamamoto M, Kanki M, Nakasone C, et al.
Mar Drugs
. 2020 Apr;
18(4).
PMID: 32326065
Inspired by the significant -glucosidase inhibitory activities of (+)- and (-)-pericosine E, we herein designed and synthesized 16 analogs of these marine natural products bearing a methoxy group instead of...
7.
Takao K, Hoshi K, Sakagami H, Shi H, Bandow K, Nagai J, et al.
Anticancer Res
. 2020 Jan;
40(1):87-95.
PMID: 31892556
Background/aim: Very few studies are available about the biological activity of 3-styrylchromones. Our previous study demonstrated the importance of methoxy group at 6-position of the chromone ring and hydroxyl group...
8.
Uesawa Y, Nagai J, Shi H, Sakagami H, Bandow K, Tomomura A, et al.
Anticancer Res
. 2019 Dec;
39(12):6489-6498.
PMID: 31810913
Background/aim: Studies of biological activity of 2-styrylchromone derivatives focusing on antioxidant, anti-inflammatory, antiviral and antitumor activity are limited. In this study, eighteen synthetic 2-styrylchromone derivatives were investigated for their cytotoxicity...
9.
Nagai J, Shi H, Sezaki N, Yoshida N, Bandow K, Uesawa Y, et al.
Anticancer Res
. 2019 Dec;
39(12):6479-6488.
PMID: 31810912
Background/aim: 4H-1-Benzopyran-4-one (chromone), present in various flavonoids as a backbone structure, has been used for the synthesis of anticancer drugs. The study aimed at investigating the cytotoxicity of eight 2-arylazolylchromones...
10.
Takao K, Endo S, Nagai J, Kamauchi H, Takemura Y, Uesawa Y, et al.
Bioorg Chem
. 2019 Sep;
92:103285.
PMID: 31561103
A series of eighteen 2-styrylchromone derivatives (see Chart 1) were synthesized and evaluated for their monoamine oxidase (MAO) A and B inhibitory activities. Many of the derivatives inhibited MAO-B comparable...